Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone

Steroids

Volumn 73, Issue 1, 2008, Pages 116-128

  Paulssen, Ruth H ^a   Moe, Bjørn ^b   Grønaas, Halvor ^b   Ørbo, Anne ^b,c  

^a Institute of Clinical Medicine   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c Faculty of Medicine   (Norway)

Author keywords

Endometrial cancer; Gene expression; Steroid hormones

Indexed keywords

PROGESTERONE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; ENDOMETRIUM CANCER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; MICROARRAY ANALYSIS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 36849086345     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2007.09.010     Document Type: Article

References (56)

1. Lindahl B., and Willen R. Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients. Anticancer Res 11 1 (1991) 403-406
2. Vereide A.B., Arnes M., Straume B., Maltau J.M., and Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 91 3 (2003) 526-533
3. Ferenczy A., and Gelfand M. The biologic significance of cytologic atypia in progesterone-treated endometrial hyperplasia. Am J Obstet Gynecol 160 1 (1989) 126-131
4. Lindahl B., Alm P., Ferno M., and Norgren A. Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment. Anticancer Res 10 3 (1990) 725-730
5. Gal D. Hormonal therapy for lesions of the endometrium. Semin Oncol 13 Suppl. 4 (1986) 33-36
6. Randall T.C., and Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90 3 (1997) 434-440
7. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 6 (1999) 1736-1744
8. Nilsson C.G., Haukkamaa M., Vierola H., and Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 17 6 (1982) 529-536
9. Montz F.J., Bristow R.E., Bovicelli A., Tomacruz R., and Kurman R.J. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 186 4 (2002) 651-657
10. Lentz S.S., Brady M.F., Major F.J., Reid G.C., and Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 14 2 (1996) 357-361
11. Lai C.H., and Huang H.J. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 18 1 (2006) 29-34
12. Amezcua C.A., Lu J.J., Felix J.C., Stanczyk F.Z., and Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 79 2 (2000) 169-176
13. Clarke C.L., and Sutherland R.L. Progestin regulation of cellular proliferation. Endocr Rev 11 2 (1990) 266-301
14. Vereide A.B., Kaino T., Sager G., and Orbo A. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 97 3 (2005) 740-750
15. Brann D.W., Hendry L.B., and Mahesh V.B. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 52 2 (1995) 113-133
16. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67 (2005) 335-376
17. Lange C.A., Richer J.K., Shen T., and Horwitz K.B. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273 47 (1998) 31308-31316
18. Revelli A., Tesarik J., and Massobrio M. Nongenomic effects of neurosteroids. Gynecol Endocrinol 12 1 (1998) 61-67
19. Simoncini T., and Genazzani A.R. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148 3 (2003) 281-292
20. Nishida M. The Ishikawa cells from birth to the present. Hum Cell 15 3 (2002) 104-117
21. Berthois Y., Katzenellenbogen J.A., and Katzenellenbogen B.S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83 8 (1986) 2496-2500
22. Soille P. Morphological image analysis: principles and applications (1999), Berlin Heidelberg, Springer Verlag (Ref Type: Book, Whole, 71-3. 1999)
23. Kerr K., Martin M., and Churchill G. Analysis of variance for gene expression microarray data. J Comput Biol 7 (2007) 819-837
24. Cleveland W. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74 368 (1979) 829-836
25. Tusher V., Tibshirani J., and Chu G. Significance analysis of microarrays applied to ionizing radiation response. Proceedings to the National Academy of Sciences, 2001; PNAS, 98 (2001) 5116-5124
26. Troyanskaya O., Cantor M., Sherlock G., Brown P., Hastie T., Tibshirani R., et al. Missing value estimation methods for DNA microarrays. Bioinformatics 17 6 (2001) 520-525
27. Brazma A., Hingkamp P., Quackenbush J., Sherlock G., Spellmann P., Stoeckert C., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29 (2001) 365-371
28. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 4 (2001) 402-408
29. Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13 9 (2003) 2129-2141
30. Mi H, Guo N, Kejariwal A, Thomas PD. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 2007; 35(Database): D247-52.
31. Chaib H., Cockrell E.K., Rubin M.A., and Macoska J.A. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 3 1 (2001) 43-52
32. Liu T., Laurell C., Selivanova G., Lundeberg J., Nilsson P., and Wiman K.G. Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis. Cell Death Differ 14 3 (2007) 411-421
33. Hernandez-Vargas H., Rodriguez-Pinilla S.M., Julian-Tendero M., Sanchez-Rovira P., Cuevas C., Anton A., et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 102 2 (2007) 157-172
34. Hegedus Z., Czibula A., and Kiss-Toth E. Tribbles: novel regulators of cell function; evolutionary aspects. Cell Mol Life Sci 63 14 (2006) 1632-1641
35. Schwarzer R., Dames S., Tondera D., Klippel A., and Kaufmann J. TRB3 is a PI 3-kinase dependent indicator for nutrient starvation. Cell Signal 18 6 (2006) 899-909
36. Jin X., Gossett D.R., Wang S., Yang D., Cao Y., Chen J., et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 91 10 (2004) 1808-1812
37. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 4 (2003) 257-262
38. Kim J.-S., Lee C., Bonifant C.L., Ressom H., and Waldman T. Activation of p53-dependent growth supprssion in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol 27 2 (2007) 662-677
39. Kovalsky O., Lung F.D., Roller P.P., and Fornace Jr. A.J. Oligomerization of human Gadd45a protein. J Biol Chem 276 42 (2001) 39330-39339
40. Sid B., Sartelet H., Bellon G., El B.H., Rath G., Delorme N., et al. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol 49 3 (2004) 245-258
41. Vigushin D.M., and Coombes R.C. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets 4 2 (2004) 205-218
42. Deroo B.J., Hewitt S.C., Peddada S.D., and Korach K.S. Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology 145 12 (2004) 5485-5492
43. Vallejo G., Ballare C., Baranao J.L., Beato M., and Saragueta P. Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells. Mol Endocrinol 19 12 (2005) 3023-3037
44. Ediger T.R., Park S.E., and Katzenellenbogen B.S. Estrogen receptor inducibility of the human Na+/H+ exchanger regulatory factor/ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50) gene involving multiple half-estrogen response elements. Mol Endocrinol 16 8 (2002) 1828-1839
45. Hayashi S.I., Eguchi H., Tanimoto K., Yoshida T., Omoto Y., Inoue A., et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10 2 (2003) 193-202
46. Haq F., Mahoney M., and Koropatnick J. Signaling events for metallothionein induction. Mutat Res 533 1/2 (2003) 211-226
47. Ace C.I., and Okulicz W.C. Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase. Reprod Biol Endocrinol 2 54 (2004) 54
48. Giudice L.C. Application of functional genomics to primate endometrium: insights into biological processes. Reprod Biol Endocrinol 4 Suppl. 1 (2006) S4 S4
49. Espey L.L., Ujioka T., Okamura H., and Richards J.S. Metallothionein-1 messenger RNA transcription in steroid-secreting cells of the rat ovary during the periovulatory period. Biol Reprod 68 5 (2003) 1895-1902
50. Penkowa M., and Hidalgo J. Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-alpha and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp Neurol 170 1 (2001) 1-14
51. Tsangaris G.T., and Tzortzatou-Stathopoulou F. Metallothionein expression prevents apoptosis: a study with antisense phosphorothioate oligodeoxynucleotides in a human T cell line. Anticancer Res 18 4A (1998) 2423-2433
52. Cherian M.G., Jayasurya A., and Bay B.H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533 1/2 (2003) 201-209
53. McCluggage W.G., Maxwell P., Hamilton P.W., and Jasani B. High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 34 1 (1999) 51-55
54. Cano-Gauci D.F., and Sarkar B. Reversible zinc exchange between metallothionein and the estrogen receptor zinc finger. FEBS Lett 386 1 (1996) 1-4
55. Qiu X.B., Shao Y.M., Miao S., and Wang L. The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci 63 22 (2006) 2560-2570
56. Wataba K., Saito T., Fukunaka K., Ashihara K., Nishimura M., and Kudo R. Over-expression of heat shock proteins in carcinogenic endometrium. Int J Cancer 91 4 (2001) 448-456